New pill aims to keep lymphoma away after CAR-T

NCT ID NCT07198373

Not yet recruiting Disease control Sponsor: Beijing GoBroad Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether taking zanubrutinib (a targeted cancer pill) for two years after CAR-T cell therapy can help keep non-Hodgkin B-cell lymphoma from coming back. About 40 adults whose cancer responded to CAR-T will receive the drug. The main goal is to see how many remain cancer-free after 24 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: zanubrutinib (a targeted cancer pill)
What this could lead to: If it works, this could help keep non-Hodgkin B-cell lymphoma in remission longer after CAR-T therapy, reducing the chance of relapse.
What could go wrong: This is a small, early-phase exploratory study (40 people) with no control group, so results may not be conclusive. Zanubrutinib can cause side effects like bleeding or infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell neoplasm B-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

B CELL LYMPHOMA

More trials for these conditions

Other studies related to the condition(s) this trial covers.